Form 4: Aligos Therapeutics Executive Julian A. Symons Adjusts Stock Option Holdings Through Exchange Program
SEC Form 4 Filing
Executive Vice President and Chief Scientific Officer of Aligos Therapeutics, Julian A. Symons, participated in an option exchange program, resulting in the cancellation of existing stock options and the grant of new options with a different exercise price.
Summary
- Julian A. Symons, Executive Vice President and Chief Scientific Officer of Aligos Therapeutics, engaged in an option exchange program.
- On February 27, 2024, existing stock options for 200,000, 105,000, and 26,250 shares were canceled.
- In exchange, on February 28, 2024, Symons received new stock options for 58,822, 74,998, and 18,750 shares, respectively, with an exercise price of $0.96 per share.
- The new options have varying vesting schedules, with some vesting one year from the grant date and others vesting over a period of 4 years.
Sentiment
Score: 5
Explanation: The document describes a routine adjustment of stock options, which is neither particularly positive nor negative. The sentiment is neutral.
Industry Context
Option exchange programs are sometimes used by companies to incentivize employees, adjust compensation packages, or manage the dilutive effect of outstanding options. The details of the program and its impact on the company's financials would require further analysis.
Comparison to Industry Standards
- Stock option exchange programs are not uncommon in the biotech industry, particularly for companies seeking to retain key personnel or adjust their capital structure.
- Similar programs have been implemented by companies like Gilead and Amgen to manage employee equity and reduce potential dilution.
- The specific terms of the Aligos Therapeutics program, such as the exchange ratio and vesting schedules, would need to be compared to industry benchmarks to assess its competitiveness and fairness.
Stakeholder Impact
- The option exchange program could impact the potential dilution of existing shareholders' equity.
- The new options provide continued incentives for Julian A. Symons to contribute to the company's success.
Key Dates
| Date | Description |
|---|---|
| 01/01/2021 | Date of original grant for 200,000 shares at $16.18 exercise price. |
| 03/04/2022 | Date of original grant for 105,000 shares at $3.06 exercise price. |
| 02/04/2022 | Date of original grant for 26,250 shares at $3.06 exercise price. |
| 02/27/2024 | Cancellation of existing stock options. |
| 02/28/2024 | Grant of new stock options with an exercise price of $0.96 per share. |
| 12/01/2030 | Expiration date for some stock options. |
| 02/04/2032 | Expiration date for some stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.